Friday, October 26, 2018 4:38:02 PM
Talon, funny you should ask.
We should all note this day as Kitty Hawk or some equivalent (Fleming moment) event, first AD treatment that is effective on AD patients following 3 years treatment. This is both a political and medical milestone day.
IMO, if Dr.G. was on his game he would jump on this and use it to declare Precision Science wins it's first battle. Dr.M. will second that. This type of trial is unique b/c people actually can LEARN SOMETHING from the trial, other than pass/fail.
Also, if the WS BP analysts were anywhere near as smart as they claim they will recognize that effective immediately the FDA will jump on this and accelerate every A2-73 trial and run the PM flag to the top of the pole. G & M have both a political and medical victory, all they have to do is say so. Dr.G. started it, Dr M collaborated and they won. PM is a giant success as a trials process. DECLARE VICTORY.
And, all A2-73 trials now be accelerated as it promises to be an effective CNS disease treatment like nothing else ever.
We should all note this day as Kitty Hawk or some equivalent (Fleming moment) event, first AD treatment that is effective on AD patients following 3 years treatment. This is both a political and medical milestone day.
IMO, if Dr.G. was on his game he would jump on this and use it to declare Precision Science wins it's first battle. Dr.M. will second that. This type of trial is unique b/c people actually can LEARN SOMETHING from the trial, other than pass/fail.
Also, if the WS BP analysts were anywhere near as smart as they claim they will recognize that effective immediately the FDA will jump on this and accelerate every A2-73 trial and run the PM flag to the top of the pole. G & M have both a political and medical victory, all they have to do is say so. Dr.G. started it, Dr M collaborated and they won. PM is a giant success as a trials process. DECLARE VICTORY.
And, all A2-73 trials now be accelerated as it promises to be an effective CNS disease treatment like nothing else ever.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
